Dyne Therapeutics, Inc.
DYN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | – | $1,084,071 | $1,149,680 | $2,402,696 |
| - Cash | $573,610 | $485,040 | $472,255 | $435,449 |
| + Debt | $16,280 | $22,264 | $23,330 | $23,988 |
| Enterprise Value | – | $621,295 | $700,755 | $1,991,235 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$104,614 | -$110,260 | -$121,870 | -$96,658 |
| % Margin | – | – | – | – |
| Net Income | -$108,041 | -$110,857 | -$115,361 | -$89,542 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.76 | -0.97 | -1.05 | -0.88 |
| % Growth | 21.6% | 7.6% | -19.3% | – |
| Operating Cash Flow | -$90,779 | -$94,703 | -$105,893 | -$84,335 |
| Capital Expenditures | -$19,185 | -$60 | -$981 | -$1,075 |
| Free Cash Flow | -$109,964 | -$94,763 | -$106,874 | -$85,410 |